CRISPR Therapeutics AG (CRSP)

51.52 +1.30 (+2.59%) USD  |  NASDAQ  |  Oct 15, 16:00
51.07 -0.45 (-0.87%) After-Hours: 06:46
More

CRISPR Therapeutics Research and Development Expense (Quarterly) : 64.95M for June 30, 2026

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2015. Start Trial.
Date Value
June 30, 2026 64.95M
March 31, 2026 66.37M
December 31, 2025 77.86M
September 30, 2025 54.50M
June 30, 2025 65.29M
March 31, 2025 67.75M
December 31, 2024 77.31M
September 30, 2024 77.36M
June 30, 2024 75.32M
March 31, 2024 71.34M
December 31, 2023 90.24M
September 30, 2023 85.77M
June 30, 2023 96.59M
March 31, 2023 94.88M
December 31, 2022 97.71M
September 30, 2022 150.46M
June 30, 2022 149.88M
March 31, 2022 142.85M
December 31, 2021 128.21M
September 30, 2021 100.00M
June 30, 2021 104.68M
March 31, 2021 87.86M
Date Value
December 31, 2020 79.80M
September 30, 2020 68.67M
June 30, 2020 57.19M
March 31, 2020 52.09M
December 31, 2019 47.33M
September 30, 2019 55.96M
June 30, 2019 39.53M
March 31, 2019 33.82M
December 31, 2018 28.80M
September 30, 2018 39.82M
June 30, 2018 25.63M
March 31, 2018 19.52M
December 31, 2017 20.03M
September 30, 2017 17.84M
June 30, 2017 17.12M
March 31, 2017 14.80M
December 31, 2016 15.57M
September 30, 2016 12.05M
June 30, 2016 8.602M
March 31, 2016 6.012M
June 30, 2015 1.486M
March 31, 2015 1.164M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Vertex Pharmaceuticals, Inc. 993.80M
Basilea Pharmaceutica AG --
Santhera Pharmaceuticals Holding AG --
BeOne Medicines Ltd. 593.46M
AC Immune SA 13.25M